Bo Cheng

Bo Cheng

Auto-generated profile, based on publicly available information

Bo Cheng

Department of Urology, the Affiliated Hospital of Southwest Medical University, Luzhou, 646000, China

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 January 2019 in BMC Cancer
Verified
Journal Article
Open access
PDF file
XQXiaofu Qiu
Xiaofu Qiu
WWWei Wang
Wei Wang
BLBijun Li
Bijun Li
BCBo Cheng
Bo Cheng
KLKangjian Lin
Kangjian Lin
GYGuosheng Yang
Guosheng Yang
Docetaxel was used to treat metastatic CRPC patients. However, Doc resistance in prostate cancer (PCa) hinders its clinical application. To understand the underlying mechanisms by which Doc resistance is developed and to find novel therapeutic target to cure Doc resistant PCa has clinical importance. We established Doc resistant cell lines and explored the role of Ezh2 in the development of Doc resistance by overexpressing its cDNA or using its inhibitor. We found that Ezh2 was induced in our established Doc resistant (DocR) cells, which was attributable to the silenced expression of miR-101-3p and miR-138-5p. Blockage of Ezh2 activity by either inhibitor or miRNA mimics could overcome Doc resistance by suppressing Doc-induced cancer stem cells populations. Mechanistically, Ezh2 activity was required for the induced expression of Nanog, Sox2 and CD44 upon Doc treatment. Targeting Ezh2 could overcome Doc resistance.